Clearside Biomedical Changes Up Pricing for IPO

By Chris Lange Updated Jan 13, 7:18AM EST · Published Jun 2, 8:40AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Clearside Biomedical Changes Up Pricing for IPO — © Thinkstock

Clearside Biomedical has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its now 7.2 million shares at $7 per share, with an overallotment option for an additional 1.08 million shares. At this price the entire offering is valued up to $57.96 million, previously the offering was valued up to roughly $74 million.

The company has been approved to list its shares on the Nasdaq Global Market under the symbol CLSD.

The underwriters for this offering are Cowen, Stifel, Needham and Wedbush PacGrow.

This late-stage clinical biopharmaceutical company is developing first-in-class drug therapies to treat blinding diseases of the eye. The current product candidates focus on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space (SCS), adjacent to the choroid, using the proprietary SCS Microinjector.

[nativounit]

With the SCS injection, Clearside’s product candidates are more directly administered to the retina and choroid, as compared to other ocular drug delivery techniques, such as intravitreal injections. The company believes SCS injection may provide a number of benefits, including lower frequency of necessary injection and faster onset of therapeutic effect.

Clearside holds the exclusive rights to develop and commercialize drugs for injection into the SCS. Its most advanced product candidates, CLS-1001 and CLS-1003, are based on commonly used ophthalmic drugs, which it believes will allow it to more efficiently and predictably pursue the regulatory approval of these product candidates under the U.S. Federal Food, Drug and Cosmetic Act.

It is estimated that there are nearly 5 million people in the United States diagnosed with these target indications and that worldwide annual sales of drugs to treat these indications were roughly $7 billion in 2014.

[wallst_email_signup]

The company intends to use the net proceeds from this offering to further develop its pipeline. The remainder will be used to fund continued research and development of earlier-stage programs, including drug discovery for potential new applications for SCS microinjection technology, and for working capital and other general corporate purposes.

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.